文献速递头颈部肿瘤放疗

NRG/RTOG 0522长期更新:放疗联合顺铂±西妥昔单抗治疗局部晚期头颈癌的随机3期试验

Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-12-19

NRG/RTOG 0522是一项随机3期试验,纳入891例局部晚期头颈癌患者,随机接受放疗联合顺铂(A组)或联合顺铂加西妥昔单抗(B组)。中位随访10.1年,加用西妥昔单抗未改善无进展生存(HR 1.06,95%CI 0.89-1.26,P=.74),10年无进展生存率A组43.6% vs B组40.2%。未改善局部区域失败、远处转移或总生存,按p16状态分层亦无获益;3-4级晚期毒性A组57.4% vs B组61.3%(P=.26)。

要点

  • 中位随访10.1年,加用西妥昔单抗未改善无进展生存(HR 1.06,P=.74)。
  • 10年无进展生存率A组43.6% vs B组40.2%。
  • 3-4级晚期毒性A组57.4% vs B组61.3%(P=.26)。

核心结论

  • 中位随访超过10年,本次更新报告证实,在放疗联合顺铂的基础上加用西妥昔单抗未改善整个队列的任何测量结局,按p16状态分层后亦未改善。

研究设计与样本

  • NRG Oncology开展的随机3期试验,2005年11月至2009年3月入组,纳入美国癌症联合委员会第6版分期T2 N2a-3 M0或T3-4 N0-3 M0的局部晚期头颈癌患者,随机接受放疗联合顺铂(A组)或不联合(B组)西妥昔单抗,共分析891例患者。

主要发现

  • 分析时452例存活,中位随访10.1年;加用西妥昔单抗未改善无进展生存(HR 1.06,95%CI 0.89-1.26,P=.74),10年无进展生存率A组43.6%(95%CI 38.8-48.4) vs B组40.2%(95%CI 35.4-45.0)。
  • 西妥昔单抗未降低局部区域失败(HR 1.21,95%CI 0.95-1.53,P=.94)或远处转移(HR 0.79,95%CI 0.54-1.14,P=.10),也未改善总生存(HR 0.97,95%CI 0.80-1.16,P=.36)。
  • 西妥昔单抗似乎未改善p16阳性口咽癌(HR 1.30,95%CI 0.87-1.93)或p16阴性口咽癌/非口咽原发(HR 0.94,95%CI 0.73-1.21)的无进展生存。
  • 3-4级晚期毒性发生率A组57.4% vs B组61.3%(P=.26)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The combination of cisplatin and radiation or cetuximab and radiation improves overall survival of patients with locoregionally advanced head and neck carcinoma. NRG Oncology conducted a phase 3 trial to test the hypothesis that adding cetuximab to radiation and cisplatin would improve progression-free survival (PFS). METHODS AND MATERIALS: Eligible patients with American Joint Committee on Cancer sixth edition stage T2 N2a-3 M0 or T3-4 N0-3 M0 were accrued from November 2005 to March 2009 and randomized to receive radiation and cisplatin without (arm A) or with (arm B) cetuximab. Outcomes were correlated with patient and tumor features. Late reactions were scored using Common Terminology Criteria for Adverse Events (version 3). RESULTS: Of 891 analyzed patients, 452 with a median follow-up of 10.1 years were alive at analysis. The addition of cetuximab did not improve PFS (hazard ratio [HR], 1.06; 95% confidence interval [CI], 0.89-1.26; P = .74), with 10-year estimates of 43.6% (95% CI, 38.8- 48.4) for arm A and 40.2% (95% CI, 35.4-45.0) for arm B. Cetuximab did not reduce locoregional failure (HR, 1.21; 95% CI, 0.95-1.53; P = .94) or distant metastasis (HR, 0.79; 95% CI, 0.54-1.14; P = .10) or improve overall survival (HR, 0.97; 95% CI, 0.80-1.16; P = .36). Cetuximab did not appear to improve PFS in either p16-positive oropharynx (HR, 1.30; 95% CI, 0.87-1.93) or p16-negative oropharynx or nonoropharyngeal primary (HR, 0.94; 95% CI, 0.73-1.21). Grade 3 to 4 late toxicity rates were 57.4% in arm A and 61.3% in arm B (P = .26). CONCLUSIONS: With a median follow-up of more than 10 years, this updated report confirms the addition of cetuximab to radiation therapy and cisplatin did not improve any measured outcome in the entire cohort or when stratifying by p16 status.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Caudell JJ, Torres-Saavedra PA, Rosenthal DI, et al. Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 36549347. doi:10.1016/j.ijrobp.2022.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。